High levels of stromelysin‐3 correlate with poor prognosis in patients with breast carcinoma

Stromelysin 3 (ST3) is a matrix metalloprotease (MMP) expressed in fibroblast‐like cells of most human invasive carcinomas. In this investigation, ST3 was measured by semiquantitative immunohistochemistry in III primary breast cancers. ST3 levels showed no correlation with tumor size, axillary‐node...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of cancer Vol. 69; no. 6; pp. 448 - 451
Main Authors:	Chenard, Marie‐Pierre, O'Siorain, Liam, Shering, Stephen, Rouyer, Nicolas, Lutz, Yves, Wolf, Catherine, Basset, Paul, Belloco, Jean‐Pierre, Duffy, Michael Joseph
Format:	Journal Article
Language:	English
Published:	New York Wiley Subscription Services, Inc., A Wiley Company 20-12-1996 Wiley-Liss Wiley
Subjects:	Biological and medical sciences Biomarkers, Tumor Breast Neoplasms - chemistry Breast Neoplasms - diagnosis Breast Neoplasms - drug therapy Breast Neoplasms - metabolism Cancer Carcinoma - chemistry Carcinoma - diagnosis Carcinoma - drug therapy Carcinoma - metabolism Carcinoma, Ductal, Breast - chemistry Carcinoma, Ductal, Breast - pathology Carcinoma, Lobular - chemistry Carcinoma, Lobular - pathology Drug Therapy, Combination Extracellular Matrix Proteins Female Gynecology. Andrology. Obstetrics Humans Immunoenzyme Techniques Immunohistochemistry - methods Life Sciences Mammary gland diseases Matrix Metalloproteinase 3 - analysis Matrix Metalloproteinase 3 - biosynthesis Medical sciences Prognosis Survival Analysis Tamoxifen - therapeutic use Treatment Outcome Tumors Human Mammary gland diseases Peptidases Carcinoma Prognosis Enzyme Hydrolases Metalloendopeptidases Tumoral marker Malignant tumor Mammary gland
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Stromelysin 3 (ST3) is a matrix metalloprotease (MMP) expressed in fibroblast‐like cells of most human invasive carcinomas. In this investigation, ST3 was measured by semiquantitative immunohistochemistry in III primary breast cancers. ST3 levels showed no correlation with tumor size, axillary‐node status or tumor grade (Scarff‐Bloom‐Richardson system; SBR) but were significantly associated with higher nuclear grade (modified SBR). In addition, ST3 levels were significantly higher in ductal than in lobular cancers. Patients with high scores of ST3 staining had a shorter disease‐free interval and shorter overall survival than patients with low scores. ST3 is thus one of the first MMPs to correlate with patient outcome in breast cancer. These findings are consistent with earlier clinical and experimental observations suggesting that ST3 contributes to breast‐cancer progression. © 1996 Wiley‐Liss, Inc.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0020-7136 1097-0215
DOI:	10.1002/(SICI)1097-0215(19961220)69:6<448::AID-IJC5>3.0.CO;2-4